Jones Financial Companies’s Insight Molecular Diagnostics IMDX Stock Holding History

Jones Financial Companies’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$340	Buy	+63	New	+$311	﹤0.01%	4808

Other funds holding IMDX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

FOR

Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jones Financial Companies's IMDX Position: Q2 2026 in Review

Jones Financial Companies opened a new position in Insight Molecular Diagnostics (IMDX) in Q2 2026: 63 shares worth $340. The stake represents ﹤0.01% of the portfolio and ranks #4808 among its holdings.

40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

Jones Financial Companies held 63 shares of Insight Molecular Diagnostics worth $340 as of Q2 2026.
Insight Molecular Diagnostics was a new Jones Financial Companies position in Q2 2026.
Insight Molecular Diagnostics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4808 holding.
40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.